| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Deepson S Shyangdan, Pamela Royle, Christine Clar, Pawana Sharma, Norman Waugh, Alisa Snait. Glucagon-like peptide analogues for type 2 diabetes mellitus. The Cochrane database of systematic reviews. issue 10. 2011-11-02. PMID:21975753. |
glp-1 regulates glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis, and by suppressing glucagon secretion, delayed gastric emptying and promoting satiety. |
2011-11-02 |
2023-08-12 |
Not clear |
| Guenther Silbernagel, Wilfried Renner, Tanja B Grammer, Sigrun R Hügl, Julia Bertram, Marcus E Kleber, Michael M Hoffmann, Bernhard R Winkelmann, Winfried März, Bernhard O Boeh. Association of TCF7L2 SNPs with age at onset of type 2 diabetes and proinsulin/insulin ratio but not with glucagon-like peptide 1. Diabetes/metabolism research and reviews. vol 27. issue 5. 2011-10-31. PMID:21384500. |
furthermore, risk alleles in tcf7l2 have been suggested to account for decreased conversion of proinsulin to insulin and decreased expression of glp-1. |
2011-10-31 |
2023-08-12 |
Not clear |
| Guenther Silbernagel, Wilfried Renner, Tanja B Grammer, Sigrun R Hügl, Julia Bertram, Marcus E Kleber, Michael M Hoffmann, Bernhard R Winkelmann, Winfried März, Bernhard O Boeh. Association of TCF7L2 SNPs with age at onset of type 2 diabetes and proinsulin/insulin ratio but not with glucagon-like peptide 1. Diabetes/metabolism research and reviews. vol 27. issue 5. 2011-10-31. PMID:21384500. |
we investigated the effect of the allelic variants rs1225537 and rs7903146 in tcf7l2 on the age at onset of type 2 diabetes, the plasma concentrations of proinsulin and glp-1, and the ratio of proinsulin to insulin in a german cohort. |
2011-10-31 |
2023-08-12 |
Not clear |
| Jacqueline A Koehler, Taylor Kain, Daniel J Drucke. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology. vol 152. issue 9. 2011-10-31. PMID:21771884. |
glp-1 regulates blood glucose through multiple mechanisms, principally inhibition of glucagon and stimulation of insulin secretion. |
2011-10-31 |
2023-08-12 |
mouse |
| Min Chen, Eralda Mema, James Kelleher, Nicholas Nemechek, Alta Berger, Jie Wang, Tao Xie, Oksana Gavrilova, Daniel J Drucker, Lee S Weinstei. Absence of the glucagon-like peptide-1 receptor does not affect the metabolic phenotype of mice with liver-specific G(s)α deficiency. Endocrinology. vol 152. issue 9. 2011-10-31. PMID:21771891. |
we previously showed that mice with liver-specific g(s)α deficiency [liver-specific g(s)α knockout (lgsko) mice] had reduced adiposity and improved glucose tolerance associated with increased glucose-stimulated insulin secretion, pancreatic islet hyperplasia, and very high serum glucagon and glucagon-like peptide 1 (glp-1) levels. |
2011-10-31 |
2023-08-12 |
mouse |
| Min Chen, Eralda Mema, James Kelleher, Nicholas Nemechek, Alta Berger, Jie Wang, Tao Xie, Oksana Gavrilova, Daniel J Drucker, Lee S Weinstei. Absence of the glucagon-like peptide-1 receptor does not affect the metabolic phenotype of mice with liver-specific G(s)α deficiency. Endocrinology. vol 152. issue 9. 2011-10-31. PMID:21771891. |
because glp-1 is known to stimulate insulin secretion and to have effects on energy balance, we mated lgsko mice with germline glp-1 receptor (glp-1r) knockout mice (glp1r(-/-)) and compared lgsko to double-knockout (lgs/glp1r(-/-)) mice to determine the contribution of excess glp-1r signaling to the lgsko phenotype. |
2011-10-31 |
2023-08-12 |
mouse |
| Min Chen, Eralda Mema, James Kelleher, Nicholas Nemechek, Alta Berger, Jie Wang, Tao Xie, Oksana Gavrilova, Daniel J Drucker, Lee S Weinstei. Absence of the glucagon-like peptide-1 receptor does not affect the metabolic phenotype of mice with liver-specific G(s)α deficiency. Endocrinology. vol 152. issue 9. 2011-10-31. PMID:21771891. |
loss of the glp-1r failed to reverse most of the metabolic features of lgsko mice, including reduced fat mass, increased glucose tolerance, and second-phase glucose-stimulated insulin secretion, islet cell hyperplasia, and very high glucagon and glp-1 levels. |
2011-10-31 |
2023-08-12 |
mouse |
| Cendrine Cabou, Christelle Vachoux, Gérard Campistron, Daniel J Drucker, Rémy Burceli. Brain GLP-1 signaling regulates femoral artery blood flow and insulin sensitivity through hypothalamic PKC-δ. Diabetes. vol 60. issue 9. 2011-10-31. PMID:21810595. |
brain glp-1 signaling regulates femoral artery blood flow and insulin sensitivity through hypothalamic pkc-δ. |
2011-10-31 |
2023-08-12 |
Not clear |
| Cendrine Cabou, Christelle Vachoux, Gérard Campistron, Daniel J Drucker, Rémy Burceli. Brain GLP-1 signaling regulates femoral artery blood flow and insulin sensitivity through hypothalamic PKC-δ. Diabetes. vol 60. issue 9. 2011-10-31. PMID:21810595. |
by analogy to pancreatic β-cells where glp-1 activates protein kinase c (pkc) to stimulate insulin secretion, we postulated that pkc enzymes would be molecular targets of brain glp-1 signaling that regulate metabolic and vascular function. |
2011-10-31 |
2023-08-12 |
Not clear |
| Marzieh Salehi, Ronald L Prigeon, David A D'Alessi. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes. vol 60. issue 9. 2011-10-31. PMID:21868791. |
the aim of this study was to establish the role of glp-1 on insulin secretion in patients with gb. |
2011-10-31 |
2023-08-12 |
Not clear |
| Eamon P Rafferty, Alastair R Wylie, Katharine H Hand, Chris E Elliott, David J Grieve, Brian D Gree. Investigating the effects of physiological bile acids on GLP-1 secretion and glucose tolerance in normal and GLP-1R(-/-) mice. Biological chemistry. vol 392. issue 6. 2011-10-28. PMID:21521075. |
glp-1 is an intestinal peptide hormone with important glucose-lowering actions, such as stimulation of insulin secretion and inhibition of glucagon secretion. |
2011-10-28 |
2023-08-12 |
mouse |
| M Jean, M Alameh, M D Buschmann, A Merzouk. Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes. Gene therapy. vol 18. issue 8. 2011-10-26. PMID:21412280. |
animals injected with the tnc chitosan 92-10-5 (dda-mw-n:p) showed glp-1 plasma levels of about fivefold higher than that in non-treated animals and the insulinotropic effect of recombinant glp-1 was shown by a threefold increase in plasma insulin concentration when compared with untreated animals. |
2011-10-26 |
2023-08-12 |
Not clear |
| Javier Jimenez-Feltstrom, Albert Salehi, Sandra Meidute Abaraviciene, Ragnar Henningsson, Ingmar Lundquis. Abnormally decreased NO and augmented CO production in islets of the leptin-deficient ob/ob mouse might contribute to explain hyperinsulinemia and islet survival in leptin-resistant type 2 obese diabetes. Regulatory peptides. vol 170. issue 1-3. 2011-10-21. PMID:21620903. |
in ob/ob islets the insulinotropic peptides glucagon, glp-1 and gip suppressed nos activities and amplified glucose-stimulated insulin release. |
2011-10-21 |
2023-08-12 |
mouse |
| D Kawamori, M Akiyama, J Hu, B Hambro, R N Kulkarn. Growth factor signalling in the regulation of α-cell fate. Diabetes, obesity & metabolism. vol 13 Suppl 1. 2011-10-14. PMID:21824253. |
our studies also reveal that glucagon-like peptide-1 (glp-1) treatment of αirko mice suppresses glucagon secretion despite absence of functional insulin receptors precluding a role for insulin in glp-1 action on α-cells in this model. |
2011-10-14 |
2023-08-12 |
mouse |
| J J Holst, M Christensen, A Lund, J de Heer, B Svendsen, U Kielgast, F K Kno. Regulation of glucagon secretion by incretins. Diabetes, obesity & metabolism. vol 13 Suppl 1. 2011-10-14. PMID:21824261. |
clinical studies of the antidiabetic effect of glp-1 in t2dm suggest that the inhibition of glucagon secretion is as important as the stimulation of insulin secretion. |
2011-10-14 |
2023-08-12 |
rat |
| Shinichiro Teramoto, Nobukazu Miyamoto, Kenji Yatomi, Yasutaka Tanaka, Hidenori Oishi, Hajime Arai, Nobutaka Hattori, Takao Urab. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. vol 31. issue 8. 2011-10-13. PMID:21487412. |
glucagon-like peptide-1 (glp-1) is an incretin hormone known to stimulate glucose-dependent insulin secretion. |
2011-10-13 |
2023-08-12 |
mouse |
| Renato O Crajoinas, Felipe T Oricchio, Thaissa D Pessoa, Bruna P M Pacheco, Lucília M A Lessa, Gerhard Malnic, Adriana C C Girard. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. American journal of physiology. Renal physiology. vol 301. issue 2. 2011-10-03. PMID:21593184. |
glucagon-like peptide-1 (glp-1) is a gut incretin hormone considered a promising therapeutic agent for type 2 diabetes because it stimulates beta cell proliferation and insulin secretion in a glucose-dependent manner. |
2011-10-03 |
2023-08-12 |
rat |
| Thi-Mai Anh Dao, Aurélie Waget, Pascale Klopp, Matteo Serino, Christelle Vachoux, Laurent Pechere, Daniel J Drucker, Serge Champion, Sylvain Barthélemy, Yves Barra, Rémy Burcelin, Eric Séré. Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PloS one. vol 6. issue 6. 2011-09-30. PMID:21673955. |
administration of rsv for 5 weeks reduced the development of glucose intolerance, and increased portal vein concentrations of both glucagon-like peptid-1 (glp-1) and insulin, and intestinal content of active glp-1. |
2011-09-30 |
2023-08-12 |
mouse |
| Thi-Mai Anh Dao, Aurélie Waget, Pascale Klopp, Matteo Serino, Christelle Vachoux, Laurent Pechere, Daniel J Drucker, Serge Champion, Sylvain Barthélemy, Yves Barra, Rémy Burcelin, Eric Séré. Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PloS one. vol 6. issue 6. 2011-09-30. PMID:21673955. |
rsv-mediated glucoregulation required a functional glp-1 receptor (glp1r) as neither glucose nor insulin levels were modulated in glp1r-/- mice. |
2011-09-30 |
2023-08-12 |
mouse |
| Shani Ben-Shlomo, Isabel Zvibel, Mati Shnell, Amir Shlomai, Elena Chepurko, Zamir Halpern, Nir Barzilai, Ran Oren, Sigal Fishma. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. Journal of hepatology. vol 54. issue 6. 2011-09-27. PMID:21145820. |
glucagon-like peptide-1 (glp-1), a gut-derived peptide degraded by dipeptidyl peptidase-4 (dpp4), stimulates insulin secretion in response to nutrients, yet its direct effect on the liver is controversial. |
2011-09-27 |
2023-08-12 |
Not clear |